Search Results - "Berends, Sophie E."

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis by Berends, Sophie E., Strik, Anne S., Löwenberg, Mark, D’Haens, Geert R., Mathôt, Ron A. A.

“…Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) of unknown etiology, probably caused by a combination of genetic and environmental factors. The…”
Get full text

Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial by Strik, Anne S., Löwenberg, Mark, Mould, Diane R., Berends, Sophie E., Ponsioen, Cyriel I., van den Brande, Jan M. H., Jansen, Jeroen M., Hoekman, Daniël R., Brandse, Johannan F., Duijvestein, Marjolijn, Gecse, Krisztina B., de Vries, Annick, Mathôt, Ron A., D'Haens, Geert R.

“…Loss of response (LOR) to infliximab (IFX) remains a challenge in the management of inflammatory bowel diseases (IBD). Proactive dosing strategies to achieve…”
Get full text

Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation by Berends, Sophie E., D'Haens, Geert R. A. M., Schaap, Tiny, Vries, Annick, Rispens, Theo, Bloem, Karien, Mathôt, Ron A. A.

“…Aims Therapeutic drug monitoring (TDM) can optimize the efficacy of infliximab (IFX) in patients with inflammatory bowel disease (IBD). Because of the delay…”
Get full text

Explaining Interpatient Variability in Adalimumab Pharmacokinetics in Patients With Crohn's Disease by Berends, Sophie E, Strik, Anne S, Van Selm, Juliet C, Löwenberg, Mark, Ponsioen, Cyriel Y, DʼHaens, Geert R, Mathôt, Ron A

“…A significant proportion of patients with Crohn's disease (CD) require dose escalation or fail adalimumab (ADL) therapy over time. ADL, a monoclonal antibody…”
Get full text

Population Pharmacokinetics of Infliximab in Children with Juvenile Idiopathic Arthritis by Nassar-Sheikh Rashid, Amara, Schonenberg-Meinema, Dieneke, Berends, Sophie E., van den Berg, J. Merlijn, Mathôt, Ron A.A.

“…The recommended infliximab (IFX) dose in (pediatric) rheumatology practice is 3-6 mg/kg every 4-8 weeks. Higher dosage regimens (>10 mg/kg) of IFX are…”
Get full text

Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples by Berends, Sophie E., Bloem, Karien, de Vries, Annick, Schaap, Tiny, Rispens, Theo, Strik, Anne S., Talwar, Rawina, Löwenberg, Mark, D'Haens, Geert R., Mathôt, Ron A.

“…Adalimumab (ADL) is a subcutaneously administered anti-tumor necrosis factor (TNF) agent used in the treatment of patients with inflammatory bowel disease…”
Get full text

Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study by Berends, Sophie E., Strik, Anne S., Jansen, Jeroen M., de Boer, Nanne K., van Egmond, Pleun S., Brandse, Johannan F., Mathôt, Ron A., D'Haens, Geert R., Löwenberg, Mark

“…Background: Golimumab (GLM) is approved for the treatment of moderate to severe ulcerative colitis (UC). Higher serum concentrations of anti-tumor necrosis…”
Get full text

Factors Influencing Clearance of Adalimumab in Patients with Crohn's Disease: A Population Pharmacokinetic Study by Berends, Sophie E, D'Haens, Geert R, Van Selm, Juliet, Strik, Anne S, Löwenberg, Mark, Ponsioen, Cyriel, Mathot, Ron

Get full text

Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients by Berends, Sophie E., van Steeg, Tamara J., Ahsman, Maurice J., Singh, Sharat, Brandse, Johannan F., D’Haens, Geert R. A. M., Mathôt, Ron A. A.

“…Ulcerative Colitis (UC) is an inflammatory bowel disease typically affecting the colon. Patients with active UC have elevated tumor necrosis factor (TNF)…”
Get full text

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial by Atalay, Selma, Berends, Sophie E, Groenewoud, Hans M M, Mathot, Ron A A, Njoo, David M, Mommers, Johannes M, Ossenkoppele, Paul M, Koetsier, Marjolein I A, Berends, Maartje A, de Vries, Annick, van de Kerkhof, Peter C M, den Broeder, Alfons A, de Jong, Elke M G J, van den Reek, Juul M P A

“…Biologics for psoriasis are registered in standard dosages. In patients with low disease activity, reduction of the dose by interval prolongation can prevent…”
Get full text

Golimumab for moderate to severe ulcerative colitis by Strik, Anne S, Berends, Sophie E, Mathôt, Ron A, D'Haens, Geert R, Löwenberg, Mark

“…Golimumab (GLM) is a subcutaneously administered human anti-tumor necrosis factor (TNF) agent that has been approved by the regulatory authorities for the…”
Get more information

Tu1822 – Ifx Serum Levels At Trough Do Not Adequately Reflect Exposure in IBD Patients by Berends, Sophie E., Mathot, Ron, Strik, Anne S., de Vries, Annick, Löwenberg, Mark, D'Haens, Geert R.

Get full text

Population pharmacokinetics of infliximab in children with juvenile idiopathic arthritis by Nassar-Sheikh Rashid, Amara, Schonenberg-Meinema, Dieneke, Berends, Sophie E., van den Berg, J. Merlijn, Mathôt, Ron A.A.

Get full text

Mo1856 - Clinical Feasibility of Dried Blood Sampling for Infliximab in IBD-Patients by Berends, Sophie E., D'Haens, Geert R., Bloem, Karien, Schaap, J, de Vries, Annick, Rispens, Theo, Mathot, Ron

Get full text

Sa1915 - Factors Influencing Clearance of Adalimumab in Patients with Crohn's Disease: A Population Pharmacokinetic Study by Berends, Sophie E., D'Haens, Geert R., Van Selm, Juliet, Strik, Anne S., Löwenberg, Mark, Ponsioen, Cyriel, Mathot, Ron

Get full text

832 – Dashboard Driven Dosing of Infliximab is Superior to Conventional Treatment in Inflammatory Bowel Disease: the Precision Randomized Controlled Trial by Strik, Anne S., Berends, Sophie E., Mould, Diane R., Mathot, Ron, Ponsioen, Cyriel, van den Brande, Jan, Jansen, Jeroen M., Hoekman, Daniel R., Brandse, Johannan F., Löwenberg, Mark, D'Haens, Geert R.

Get full text

Mo1845 - Higher Serum Concentrations of Vedolizumab are Associated with Superior Endoscopic Outcomes in Crohn's Disease: Data from the Love-CD Trial by Berends, Sophie E., Löwenberg, Mark, Baert, Filip J., Mathot, Ron, Clasquin, E, Van Der Woude, Christien Janneke, Hoentjen, Frank, Bossuyt, Peter, Franchimont, Denis, Rispens, Theo, de Vries, Annick, Vermeire, Severine, D'Haens, Geert R.

Get full text

Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial by Atalay, Selma, Berends, Sophie E., Groenewoud, Hans M. M., Mathot, Ron A. A., Njoo, David M., Mommers, Johannes M., Ossenkoppele, Paul M., Koetsier, Marjolein I. A., Berends, Maartje A., de Vries, Annick, van de Kerkhof, Peter C. M., den Broeder, Alfons A., de Jong, Elke M. G. J., van den Reek, Juul M. P. A.

“…Biologics for psoriasis are registered in standard dosages. In patients with low disease activity, reduction of the dose by interval prolongation can prevent…”
Get full text